Coalition letter asking Georgia’s governor to pause Medicaid procedural terminations to ensure that those who are currently enrolled in Medicaid can maintain their coverage, if eligible, or transition to other forms of coverage.
Site Search
The letter responds to Select Health’s changes in coverage criteria, urging the health plan to cover Trikafta for all people with cystic fibrosis who meet eligibility requirements per the U.S. Food and Drug Administration label.
Ad hoc patient advocacy coalition letter to the Center for Medicare and Medicaid Services on the implementation of the Medicare Part D maximum monthly out-of-pocket cap option.
Partnership for Protecting Coverage statement urging the Administration to take immediate action to protect patients’ Medicaid coverage amid the public health emergency unwinding.
CF Foundation letter to the Wisconsin governor thanking him for funding the Wisconsin Chronic Disease Program and Wisconsin Medicaid in the 2023-2025 biennial budget.
Partnership for Protecting Coverage letter to the U.S. Department of Health and Human Services outlining patient priorities for the 2025 Notice of Benefits and Payment Parameters.
CF Foundation letter to the Ohio governor and state legislature thanking them for funding the Children and Youth with Special Health Needs program and Ohio Medicaid in the 2024-2025 budget.
CF Foundation letter to the Senate Finance Committee in support of the Modernization and Ensuring PBM Accountability Act which would enhance accountability and address the opaque influence of pharmacy benefit managers.
The CF Foundation writes to Michigan’s House Committee on Insurance and Financial Services to provide comments on SB 483: The Prescription Drug Cost and Affordability Review Act, which would create a prescription drug affordability board in the state.
In a letter sent to Colorado’s Prescription Drug Affordable Board, the Cystic Fibrosis Foundation provides feedback on the board’s review of Trikafta®, including concerns around the board’s proposed methodology, and provides a compilation of published data on Trikafta’s effects on clinical outcomes and other health care utilization.